173 related articles for article (PubMed ID: 22190393)
1. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009.
Trotter CL; Findlow H; Borrow R
Clin Vaccine Immunol; 2012 Feb; 19(2):219-22. PubMed ID: 22190393
[TBL] [Abstract][Full Text] [Related]
2. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
[TBL] [Abstract][Full Text] [Related]
3. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
4. Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.
Memish ZA; Yezli S; Almasri M; Assiri A; Turkestani A; Findlow H; Bai X; Borrow R
Int J Infect Dis; 2014 Nov; 28():171-5. PubMed ID: 25307887
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
6. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.
Gill CJ; Ram S; Welsch JA; Detora L; Anemona A
Vaccine; 2011 Dec; 30(1):29-34. PubMed ID: 22075087
[TBL] [Abstract][Full Text] [Related]
7. Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
Findlow H; Sow S; Borrow R; Tapia M; Haidara FC; Akinsola AK; Idoko OT; Diallo F; Adegbola R; Tang Y; Parulekar V; Chadha H; Mabey L; Holme D; Townsend K; Chaumont J; Laforce FM; Kulkarni PS; Marchetti E; Viviani S; Hassan-King M; Preziosi MP
Clin Vaccine Immunol; 2011 Sep; 18(9):1492-6. PubMed ID: 21752951
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
Trotter CL; Borrow R; Findlow J; Holland A; Frankland S; Andrews NJ; Miller E
Clin Vaccine Immunol; 2008 Nov; 15(11):1694-8. PubMed ID: 18827191
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.
Trotter C; Findlow J; Balmer P; Holland A; Barchha R; Hamer N; Andrews N; Miller E; Borrow R
Clin Vaccine Immunol; 2007 Jul; 14(7):863-8. PubMed ID: 17494636
[TBL] [Abstract][Full Text] [Related]
10. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.
Joseph H; Balmer P; Bybel M; Papa T; Ryall R; Borrow R
Clin Diagn Lab Immunol; 2004 Jan; 11(1):1-5. PubMed ID: 14715537
[TBL] [Abstract][Full Text] [Related]
11. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
12. Prospective survey on carriage of Neisseria meningitidis and protective immunity to meningococci in schoolchildren in Niamey (Niger): focus on serogroup W135.
Amadou Hamidou A; Djibo S; Elhaj Mahamane A; Moussa A; Findlow H; Sidikou F; Cisse R; Garba A; Borrow R; Chanteau S; Boisier P
Microbes Infect; 2006 Jul; 8(8):2098-104. PubMed ID: 16777457
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
[TBL] [Abstract][Full Text] [Related]
14. Serological specificities of murine hybridoma monoclonal antibodies against Neisseria meningitidis serogroups B, C, Y, and W135 and evaluation of their usefulness as serogrouping reagents by indirect whole-cell enzyme-linked immunosorbent assay.
Tsang RS; Zollinger WD
Clin Diagn Lab Immunol; 2005 Jan; 12(1):152-6. PubMed ID: 15643000
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
Siberry GK; Williams PL; Lujan-Zilbermann J; Warshaw MG; Spector SA; Decker MD; Heckman BE; Demske EF; Read JS; Jean-Philippe P; Kabat W; Nachman S;
Pediatr Infect Dis J; 2010 May; 29(5):391-6. PubMed ID: 20431379
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.
Blanchard-Rohner G; Snape MD; Kelly DF; O'Connor D; John T; Kibwana E; Parks H; Ford K; Dull PM; Pollard AJ
Pediatr Infect Dis J; 2013 Jul; 32(7):768-76. PubMed ID: 23538521
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays.
Lucidarme J; Louth J; Townsend-Payne K; Borrow R
Methods Mol Biol; 2019; 1969():169-179. PubMed ID: 30877677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
